Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting : An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
Copyright © 2023. Published by Elsevier Inc..
The first series of chimeric antigen receptor T (CAR-T) cell therapy products were approved in 2017 to 2019 and have shown remarkable efficacy in both clinical trials and the real-world setting, but at the cost of prolonged patient hospitalization. As the toxicity management protocols were refined, the concept of cellular therapy administered in the outpatient setting gained steam, and single institutions began to perform certain aspects of CAR-T monitoring in the outpatient setting for select patients. However, there are many considerations for a successful outpatient program. In anticipation of increasing use of CAR-T-cell therapy in the outpatient setting as a mechanism to overcome frequent hospital bed shortages and high cost of inpatient care, the American Society for Transplantation and Cellular Therapy convened a group of experts in hematology, oncology, and cellular therapy to provide a comprehensive review of the existing publications on outpatient CAR-T cell therapy, discuss selected ongoing clinical trials of outpatient CAR-T, and describe strategies to optimize safety without compromising efficacy for patients treated and monitored in the outpatient setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Transplantation and cellular therapy - 30(2024), 2 vom: 01. Feb., Seite 131-142 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Oluwole, Olalekan O [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.02.2024 Date Revised 05.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jtct.2023.11.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36443161X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36443161X | ||
| 003 | DE-627 | ||
| 005 | 20240205231921.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtct.2023.11.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1281.xml |
| 035 | |a (DE-627)NLM36443161X | ||
| 035 | |a (NLM)37951502 | ||
| 035 | |a (PII)S2666-6367(23)01675-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Oluwole, Olalekan O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting |b An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2024 | ||
| 500 | |a Date Revised 05.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a The first series of chimeric antigen receptor T (CAR-T) cell therapy products were approved in 2017 to 2019 and have shown remarkable efficacy in both clinical trials and the real-world setting, but at the cost of prolonged patient hospitalization. As the toxicity management protocols were refined, the concept of cellular therapy administered in the outpatient setting gained steam, and single institutions began to perform certain aspects of CAR-T monitoring in the outpatient setting for select patients. However, there are many considerations for a successful outpatient program. In anticipation of increasing use of CAR-T-cell therapy in the outpatient setting as a mechanism to overcome frequent hospital bed shortages and high cost of inpatient care, the American Society for Transplantation and Cellular Therapy convened a group of experts in hematology, oncology, and cellular therapy to provide a comprehensive review of the existing publications on outpatient CAR-T cell therapy, discuss selected ongoing clinical trials of outpatient CAR-T, and describe strategies to optimize safety without compromising efficacy for patients treated and monitored in the outpatient setting | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Cellular therapy | |
| 650 | 4 | |a Chimeric antigen receptor (CAR) T cells | |
| 650 | 4 | |a Cytokine release syndrome (CRS) | |
| 650 | 4 | |a Immune effector cell-associated neurotoxicity syndrome (ICANS) | |
| 650 | 4 | |a Outpatient monitoring | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Dholaria, Bhagirathbhai |e verfasserin |4 aut | |
| 700 | 1 | |a Knight, Tristan E |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Tania |e verfasserin |4 aut | |
| 700 | 1 | |a Locke, Frederick L |e verfasserin |4 aut | |
| 700 | 1 | |a Ramsdell, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Nikiforow, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Hashmi, Hamza |e verfasserin |4 aut | |
| 700 | 1 | |a Mooney, Kathy |e verfasserin |4 aut | |
| 700 | 1 | |a Bhaskar, Shakthi T |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Katrina |e verfasserin |4 aut | |
| 700 | 1 | |a Gatwood, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Baer, Brittney |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Larry D |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Hamadani, Mehdi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation and cellular therapy |d 2021 |g 30(2024), 2 vom: 01. Feb., Seite 131-142 |w (DE-627)NLM307596486 |x 2666-6367 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:131-142 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtct.2023.11.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 2 |b 01 |c 02 |h 131-142 | ||